Featured News

Newly released data from Chugai Pharmaceuticals shows their drug candidate DONQ52 potently blocks gluten-specific t-cells and is ready for continued development. So, what does this mean for the celiac disease community?

We are delighted to report at the beginning of this calendar year two significant milestones in our ongoing efforts to compel the federal government to treat celiac disease with the seriousness it deserves.  

ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.

The Celiac Disease Foundation is committed to representing the celiac disease patient voice in policy and healthcare reform, and can better do so alongside strong allies with common goals. To this end, on March 20, 2018, Alana Broe, Legislative Analyst for the Celiac Disease Foundation, attended the National Coalition of Autoimmune Patient Groups (NCAPG) meeting.…

Celiac Disease Foundation Chief Executive Officer, Marilyn Geller, attended The State of Autoimmune Disease: A National Summit at the National Press Club in Washington, D.C. The Summit explored the current trends in diagnosis, treatment, and therapies, presented by experts in research, environment, advocacy, and patient issues.

Celiac Disease Foundation is pleased to announce our participation in the Autoimmune Research Network, known as ARNet. ARNet is a network of autoimmune disease advocacy organizations that will foster research into celiac disease and related autoimmune conditions. In consonance with CDF’s Strategic Plan to increase national awareness of the ramifications of undiagnosed celiac disease, the first goal of…

On March 23rd, join CDF at The State of Autoimmune Disease: A National Summit at the National Press Club in Washington, DC. The summit will bring together leading experts in research, environment, advocacy and patient issues to explore the most current trends in autoimmune disease diagnosis, treatments and therapies.